Search hospitals > Tennessee > Nashville
Tennessee Oncology PLLC
Claim this profileNashville, Tennessee 37203
Global Leader in Breast Cancer
Global Leader in Non-Small Cell Lung Cancer
Conducts research for Tumors
Conducts research for Cancer
Conducts research for Lung Cancer
296 reported clinical trials
11 medical researchers
Summary
Tennessee Oncology PLLC is a medical facility located in Nashville, Tennessee. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Tumors, Cancer, Lung Cancer and other specialties. Tennessee Oncology PLLC is involved with conducting 296 clinical trials across 154 conditions. There are 11 research doctors associated with this hospital, such as Melissa Johnson, MD, Erika P Hamilton, Meredith A McKean, and David R. Spigel, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
HER2 negative
Top PIs
Melissa Johnson, MDSarah Cannon Research Institute5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Tumors
59 reported clinical trials
86 drugs studied
Erika P HamiltonSarah Cannon Research Institute4 years of reported clinical research
Expert in Breast Cancer
Expert in Ovarian Cancer
53 reported clinical trials
76 drugs studied
Meredith A McKeanSarah Cannon Research Institute1 year of reported clinical research
Expert in Solid Tumors
Expert in Tumors
34 reported clinical trials
66 drugs studied
David R. Spigel, MDTennessee Oncology3 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Tumors
28 reported clinical trials
53 drugs studied
Clinical Trials running at Tennessee Oncology PLLC
Breast Cancer
Solid Tumors
Tumors
Non-Small Cell Lung Cancer
Lymphoma
Cancer
Follicular Lymphoma
Prostate Cancer
Non-Hodgkin's Lymphoma
Ovarian Cancer
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Recruiting4 awards Phase 3
Sacituzumab Govitecan
for Breast Cancer
The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available standard treatments, such as paclitaxel, nab-paclitaxel or capecitabine. The primary objective is to compare the effect of SG relative to the treatment of physician's choice (TPC) on progression-free survival (PFS).
Recruiting2 awards Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Tennessee Oncology PLLC?
Tennessee Oncology PLLC is a medical facility located in Nashville, Tennessee. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Tumors, Cancer, Lung Cancer and other specialties. Tennessee Oncology PLLC is involved with conducting 296 clinical trials across 154 conditions. There are 11 research doctors associated with this hospital, such as Melissa Johnson, MD, Erika P Hamilton, Meredith A McKean, and David R. Spigel, MD.